Want to see PTN full AI Analyst Report?
Earnings Data
Report Date
Nov 16, 2026Before Open (Confirmed)
Period Ending
2027 (Q1)Consensus EPS Forecast
―Last Year’s EPS
4.26Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Balanced: The call highlighted meaningful near-term commercial validation via upfront collaboration revenue, materially reduced net loss, reduced operating cash burn, strong partnership-driven non-dilutive funding and clear progress across peptide and oral MC4R programs (including IP development). Offsetting these positives are increased operating costs, a limited cash runway to mid-2027 that creates funding risk, a deprioritized earlier oral candidate and timing/competitive risks (notably Rhythm's approved product). Clinical risk around hyperpigmentation and the need for further IND/clinic-readout milestones keep the outlook cautious.Company Guidance
Revenue Recognition and Improved Loss Profile
Recognized $3.9M in collaboration and license revenue in Q3 FY2026 vs $0 in prior year; net loss narrowed to $1.4M (-$0.37 per share) from $4.8M (-$9.13 per share) in the prior year period (net loss improved ~70.8%), driven primarily by upfront collaboration revenue recognition.
Reduced Operating Cash Use and Liquidity
Net cash used in operations decreased to $4.4M in the quarter from $5.4M in the prior year period (≈18.5% reduction). Cash and cash equivalents were $10.2M plus approximately $2.2M of receivables expected to collect by June 30, 2026; company expects existing cash and receivables to fund operations through June 30, 2027 (contingent on timing of expenses).
Material Non-Dilutive Funding via Partnerships
Received EUR 7.5M (~$8.8M) in upfront and milestone payments from Boehringer Ingelheim in H2 2025 and $3.8M upfront from sublicensing PL-9643 to Altanispac Labs in Jan 2026; these transactions generate near-term non-dilutive capital and potential future milestones/royalties.
Peptide MC4R Agonist Program Advancing Toward Regulatory Submission
Once-weekly MC4R-selective peptide (lead clinical asset) remains on track for a calendar Q4 2026 regulatory submission; IND-enabling studies are underway and management emphasizes focus on tolerability, usability and long-term patient adherence.
Next-Generation Oral Small Molecule Progress
Preclinical candidates demonstrate substantially improved MC4R selectivity, minimal MC1R activity and increased potency versus earlier compounds; goal is lower dosing and meaningful reduction/elimination of MC1R-mediated hyperpigmentation. Targeting IND in first half of calendar 2027.
Platform Leverage and Additional Value Drivers
PL-8177 (ulcerative colitis) positioned for potential partnering after positive Phase II PoC; new intellectual property around MC4R selectivity being developed; strategy of sublicensing/partnering is creating multiple potential long-term value drivers.
PTN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PTN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $19.70 | $16.55 | -16.01% |
Feb 17, 2026 | $17.39 | $17.59 | +1.15% |
Nov 13, 2025 | $11.04 | $10.80 | -2.17% |
Oct 07, 2025 | $7.90 | $7.27 | -7.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Palatin Technologies (PTN) report earnings?
Palatin Technologies (PTN) is schdueled to report earning on Nov 16, 2026, Before Open (Confirmed).
What is Palatin Technologies (PTN) earnings time?
Palatin Technologies (PTN) earnings time is at Nov 16, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PTN EPS forecast?
Currently, no data Available